Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05297565 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 14
- Enrollment target
NCT05297565 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 14 participants.
The verdict
NCT05297565, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of subcutaneous nivolumab vs intravenous nivolumab in participants with completely resected Stage IIIA/B/C/D or Stage IV melanoma.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Nivolumab/rHuPH20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-08-02 |
| Est. Completion | 2024-02-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05297565
The ClinicalTrials.gov registry entry for NCT05297565 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT05297565 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05297565 about?
NCT05297565 is a clinical study titled "A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection". The purpose of this study is to assess the safety and tolerability of subcutaneous nivolumab vs intravenous nivolumab in participants with completely resected Stage IIIA/B/C/D or Stage IV melanoma.
What is the current status of trial NCT05297565?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 14 participants. The study started on 2022-08-02. Estimated completion is 2024-02-08.
What interventions are being tested in trial NCT05297565?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Nivolumab/rHuPH20 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05297565?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.